Menu
Live News EQUITY M impact

TSHA Completes Dosing

Taysha Gene Therapies completes dosing in REVEAL pivotal trial and reports longer-term clinical data from Part A of REVEAL Phase 1/2 trials for TSHA-102

TSHA

TSHA - Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome